Y-mAbs to Announce Second Quarter 2025 Financial and Operating Results on August 8, 2025
Y-mAbs Therapeutics (NASDAQ:YMAB), a commercial-stage biopharmaceutical company specializing in antibody-based cancer therapeutics, will release its Q2 2025 financial results on Friday, August 8, 2025, before market open.
Due to the previously announced transaction with SERB Pharmaceuticals affiliates, the company will not conduct an earnings conference call for this quarter.
Y-mAbs Therapeutics (NASDAQ:YMAB), un'azienda biofarmaceutica in fase commerciale specializzata in terapie oncologiche basate su anticorpi, pubblicherà i suoi risultati finanziari del secondo trimestre 2025 venerdì 8 agosto 2025, prima dell'apertura dei mercati.
A causa della transazione precedentemente annunciata con le affiliate di SERB Pharmaceuticals, la società non terrà una conference call sugli utili per questo trimestre.
Y-mAbs Therapeutics (NASDAQ:YMAB), una empresa biofarmacéutica en etapa comercial especializada en terapias contra el cáncer basadas en anticuerpos, publicará sus resultados financieros del segundo trimestre de 2025 el viernes 8 de agosto de 2025, antes de la apertura del mercado.
Debido a la transacción anunciada previamente con las afiliadas de SERB Pharmaceuticals, la compañía no realizará una llamada de conferencia de resultados para este trimestre.
Y-mAbs Therapeutics (NASDAQ:YMAB)는 항체 기반 암 치료제를 전문으로 하는 상업 단계의 바이오제약 회사로, 2025년 2분기 재무 실적을 2025년 8월 8일 금요일 시장 개장 전에 발표할 예정입니다.
이전에 공지된 SERB Pharmaceuticals 계열사와의 거래로 인해, 이번 분기에는 실적 컨퍼런스 콜을 진행하지 않습니다.
Y-mAbs Therapeutics (NASDAQ:YMAB), une société biopharmaceutique en phase commerciale spécialisée dans les thérapies anticancéreuses à base d'anticorps, publiera ses résultats financiers du deuxième trimestre 2025 le vendredi 8 août 2025, avant l'ouverture des marchés.
En raison de la transaction annoncée précédemment avec les filiales de SERB Pharmaceuticals, la société ne tiendra pas de conférence téléphonique sur les résultats pour ce trimestre.
Y-mAbs Therapeutics (NASDAQ:YMAB), ein biopharmazeutisches Unternehmen in der kommerziellen Phase, das sich auf Antikörper-basierte Krebstherapien spezialisiert hat, wird seine Finanzergebnisse für das zweite Quartal 2025 am Freitag, den 8. August 2025, vor Börsenöffnung veröffentlichen.
Aufgrund der zuvor angekündigten Transaktion mit den Tochtergesellschaften von SERB Pharmaceuticals wird das Unternehmen in diesem Quartal keine Gewinnkonferenzschaltung durchführen.
- None.
- None.
PRINCETON, N.J., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of antibody-based therapeutics for the treatment of cancer, today announced it will report results for the second quarter 2025 before the market open on Friday, August 8, 2025.
In light of the previously announced transaction with affiliated entities of SERB Pharmaceuticals, Y-mAbs will not be hosting an earnings conference call.
About Y-mAbs
Y-mAbs is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, radioimmunotherapy and antibody-based therapeutic cancer products. The Company’s broad and advanced commercial product pipeline includes the anti-GD2 therapy DANYELZA® (naxitamab-gqgk), the first FDA-approved treatment for patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow after a partial response, minor response, or stable disease to prior therapy. The Company’s technologies include its investigational Self-Assembly DisAssembly (“SADA”) Pretargeted Radioimmunotherapy Platform (“PRIT”) and bispecific antibodies generated using the Y-BiClone platform.
SADA®, SADA PRIT™, DANYELZA® and Y-mAbs® are registered trademarks of Y-mAbs Therapeutics, Inc.
CONTACTS Investor and Media Contacts: Courtney Dugan VP, Head of Investor Relations cdu@ymabs.com Aaron Palash / Fouad Boutros Joele Frank, Wilkinson Brimmer Katcher apalash@joelefrank.com fboutros@joelefrank.com 212-355-4449
FAQ
When will Y-mAbs (NASDAQ:YMAB) release Q2 2025 earnings?
Why isn't Y-mAbs holding a Q2 2025 earnings conference call?
What is Y-mAbs Therapeutics' main business focus?
Where can investors access Y-mAbs' Q2 2025 financial results?
